Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +69.37% and +20.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?